Literature DB >> 1419863

Survival of asbestos insulation workers with mesothelioma.

J Ribak1, I J Selikoff.   

Abstract

Malignant mesothelioma is a lethal disease. It is rare in the general population; however, workers exposed to asbestos suffer significant burdens of the neoplasm. The survival time of 457 consecutive fatal cases of pleural and peritoneal mesothelioma that occurred among 17,800 asbestos insulation workers observed prospectively from 1 January 1967 to 1 January 1987 was studied. Mean survival time from initial presentation of the disease to death was 11.4 months for the pleural mesothelioma patients compared with 7.4 months for the peritoneal group. This difference was statistically significant. Mean survival time from diagnosis to death was shorter for both groups of patients: 8.4 months for pleural mesothelioma v 5.8 months for the peritoneal cases. In conclusion, survival time in mesothelioma patients is short; most die within a year from the onset of the initial symptoms. No effective therapy is yet available.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1419863      PMCID: PMC1012150          DOI: 10.1136/oem.49.10.732

Source DB:  PubMed          Journal:  Br J Ind Med        ISSN: 0007-1072


  18 in total

1.  ASBESTOS EXPOSURE AND NEOPLASIA.

Authors:  I J SELIKOFF; J CHURG; E C HAMMOND
Journal:  JAMA       Date:  1964-04-06       Impact factor: 56.272

2.  Use of thermal manikins in environmental ergonomics.

Authors:  D P Wyon
Journal:  Scand J Work Environ Health       Date:  1989       Impact factor: 5.024

3.  Pleural mesothelioma treated by fast neutron therapy.

Authors:  P R Blake; M Catterall; P A Emerson
Journal:  Thorax       Date:  1985-01       Impact factor: 9.139

Review 4.  Current concepts: malignant mesothelioma.

Authors:  K H Antman
Journal:  N Engl J Med       Date:  1980-07-24       Impact factor: 91.245

5.  Malignant mesothelioma in a cohort of asbestos insulation workers: clinical presentation, diagnosis, and causes of death.

Authors:  J Ribak; R Lilis; Y Suzuki; L Penner; I J Selikoff
Journal:  Br J Ind Med       Date:  1988-03

6.  An unusual presentation of malignant mesothelioma: the incidental finding of tumor in the hernia sac during herniorrhaphy.

Authors:  J Brenner; P P Sordillo; G B Magill
Journal:  J Surg Oncol       Date:  1981       Impact factor: 3.454

7.  Seventeen year survival in a patient with malignant peritoneal mesothelioma.

Authors:  J Brenner; P P Sordillo; G B Magill
Journal:  Clin Oncol       Date:  1981-09

8.  Diagnosis and prognosis in malignant pleural mesothelioma: a prospective study.

Authors:  G Mårtensson; B Hagmar; L Zettergren
Journal:  Eur J Respir Dis       Date:  1984-04

9.  Diffuse malignant mesothelioma. Prospective evaluation of 69 patients.

Authors:  A P Chahinian; T F Pajak; J F Holland; L Norton; R M Ambinder; E M Mandel
Journal:  Ann Intern Med       Date:  1982-06       Impact factor: 25.391

10.  Malignant mesothelioma. The University of Minnesota experience.

Authors:  N J Vogelzang; S M Schultz; A M Iannucci; B J Kennedy
Journal:  Cancer       Date:  1984-02-01       Impact factor: 6.860

View more
  5 in total

Review 1.  Statement on malignant mesothelioma in the United Kingdom.

Authors: 
Journal:  Thorax       Date:  2001-04       Impact factor: 9.139

2.  BTS statement on malignant mesothelioma in the UK, 2007.

Authors: 
Journal:  Thorax       Date:  2007-11       Impact factor: 9.139

3.  Malignant pleural mesothelioma treated in Clinic for Pulmonary Diseases and Tuberculosis "Podhrastovi" in ten-year period (from 1998 to 2007).

Authors:  Vesna Cukić; Aida Ustamujić; Vladimir Lovre; Hasan Zutić; Sadika Genjac; Mina Masić-Zecević
Journal:  Bosn J Basic Med Sci       Date:  2008-11       Impact factor: 3.363

Review 4.  Lung cancer * 8: Management of malignant mesothelioma.

Authors:  C Parker; E Neville
Journal:  Thorax       Date:  2003-09       Impact factor: 9.139

5.  A trial of intra-pleural bacterial immunotherapy in malignant pleural mesothelioma (TILT) - a randomised feasibility study using the trial within a cohort (TwiC) methodology.

Authors:  Anna C Bibby; Natalie Zahan-Evans; Emma Keenan; Charles Comins; John E Harvey; Helen Day; Najib M Rahman; Janet E Fallon; Rachael Gooberman-Hill; Nick A Maskell
Journal:  Pilot Feasibility Stud       Date:  2022-09-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.